Reference
1. Shepard DS, Undurraga EA, Halasa YA, Stanaway JD. The global economic
burden of dengue: a systematic analysis. The Lancet infectious diseases.
2016;16(8):935-41.
2. Malavige GN, Wijewickrama A, Fernando S, Jeewandara C, Ginneliya A,
Samarasekara S, et al. A preliminary study on efficacy of rupatadine for
the treatment of acute dengue infection. Sci Rep. 2018;8(1):3857.
3. Ang LW, Thein TL, Ng Y, Boudville IC, Chia PY, Lee VJM, et al. A
15-year review of dengue hospitalizations in Singapore: Reducing
admissions without adverse consequences, 2003 to 2017. PLoS neglected
tropical diseases. 2019;13(5):e0007389.
4. Tricou V, Minh NN, Van TP, Lee SJ, Farrar J, Wills B, et al. A
randomized controlled trial of chloroquine for the treatment of dengue
in Vietnamese adults. PLoS neglected tropical diseases. 2010;4(8):e785.
5. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et
al. The global distribution and burden of dengue. Nature.
2013;496(7446):504-7.
6. Murhekar MV, Kamaraj P, Kumar MS, Khan SA, Allam RR, Barde P, et al.
Burden of dengue infection in India, 2017: a cross-sectional population
based serosurvey. Lancet Glob Health. 2019;7(8):e1065-e73.
7. Malavige GN, Ogg GS. Pathogenesis of vascular leak in dengue virus
infection. Immunology. 2017;151(3):261-9.
8. Gomes L, Fernando S, Fernando RH, Wickramasinghe N, Shyamali NL, Ogg
GS, et al. Sphingosine 1-phosphate in acute dengue infection. PloS one.
2014;9(11):e113394.
9. Jeewandara C, Gomes L, Wickramasinghe N, Gutowska-Owsiak D, Waithe D,
Paranavitane SA, et al. Platelet activating factor contributes to
vascular leak in acute dengue infection. PLoS neglected tropical
diseases. 2015;9(2):e0003459.
10. Puerta-Guardo H, Glasner DR, Harris E. Dengue Virus NS1 Disrupts the
Endothelial Glycocalyx, Leading to Hyperpermeability. PLoS pathogens.
2016;12(7):e1005738.
11. Hottz ED, Lopes JF, Freitas C, Valls-de-Souza R, Oliveira MF, Bozza
MT, et al. Platelets mediate increased endothelium permeability in
dengue through NLRP3-inflammasome activation. Blood.
2013;122(20):3405-14.
12. St John AL, Rathore AP, Raghavan B, Ng ML, Abraham SN. Contributions
of mast cells and vasoactive products, leukotrienes and chymase, to
dengue virus-induced vascular leakage. Elife. 2013;2:e00481.
13. Jeewandara C, Gomes L, Udari S, Paranavitane SA, Shyamali NL, Ogg
GS, et al. Secretory phospholipase A2 in the pathogenesis of acute
dengue infection. Immun Inflamm Dis. 2017;5(1):7-15.
14. Bennett M, Gilroy DW. Lipid Mediators in Inflammation. Microbiol
Spectr. 2016;4(6).
15. Ogawa Y, Calhoun WJ. The role of leukotrienes in airway
inflammation. The Journal of allergy and clinical immunology.
2006;118(4):789-98; quiz 99-800.
16. Joris I, Majno G, Corey EJ, Lewis RA. The mechanism of vascular
leakage induced by leukotriene E4. Endothelial contraction. The American
journal of pathology. 1987;126(1):19-24.
17. Loke WM, Chow AY, Lam Mok Sing K, Lee CY, Halliwell B, Lim EC, et
al. Augmentation of 5-lipoxygenase activity and expression during dengue
serotype-2 infection. Virology journal. 2013;10:322.
18. WHO, editor. Comprehensive guidelines for prevention and control of
dengue fever and dengue haemorrhagic fever. SEARO, New Delhi, India:
World Health Organization; 2011.
19. Fernando S, Wijewickrama A, Gomes L, Punchihewa CT, Madusanka SD,
Dissanayake H, et al. Patterns and causes of liver involvement in acute
dengue infection. BMC infectious diseases. 2016;16:319.
20. Tissera H, Rathore APS, Leong WY, Pike BL, Warkentien TE, Farouk FS,
et al. Chymase Level Is a Predictive Biomarker of Dengue Hemorrhagic
Fever in Pediatric and Adult Patients. The Journal of infectious
diseases. 2017;216(9):1112-21.
21. Cui L, Lee YH, Thein TL, Fang J, Pang J, Ooi EE, et al. Serum
Metabolomics Reveals Serotonin as a Predictor of Severe Dengue in the
Early Phase of Dengue Fever. PLoS neglected tropical diseases.
2016;10(4):e0004607.
22. Furuta T, Murao LA, Lan NT, Huy NT, Huong VT, Thuy TT, et al.
Association of mast cell-derived VEGF and proteases in Dengue shock
syndrome. PLoS neglected tropical diseases. 2012;6(2):e1505.
23. Rathore AP, Mantri CK, Aman SA, Syenina A, Ooi J, Jagaraj CJ, et al.
Dengue virus-elicited tryptase induces endothelial permeability and
shock. The Journal of clinical investigation. 2019;130:4180-93.
24. Chiu CY, Tsai MH, Yao TC, Tu YL, Hua MC, Yeh KW, et al. Urinary LTE4
levels as a diagnostic marker for IgE-mediated asthma in preschool
children: a birth cohort study. PloS one. 2014;9(12):e115216.
25. Syenina A, Jagaraj CJ, Aman SA, Sridharan A, St John AL. Dengue
vascular leakage is augmented by mast cell degranulation mediated by
immunoglobulin Fcgamma receptors. Elife. 2015;4.
26. Asano K, Lilly CM, O’Donnell WJ, Israel E, Fischer A, Ransil BJ, et
al. Diurnal variation of urinary leukotriene E4 and histamine excretion
rates in normal subjects and patients with mild-to-moderate asthma. The
Journal of allergy and clinical immunology. 1995;96(5 Pt 1):643-51.
27. Capra V, Thompson MD, Sala A, Cole DE, Folco G, Rovati GE.
Cysteinyl-leukotrienes and their receptors in asthma and other
inflammatory diseases: critical update and emerging trends. Med Res Rev.
2007;27(4):469-527.
28. Wang TT, Sewatanon J, Memoli MJ, Wrammert J, Bournazos S, Bhaumik
SK, et al. IgG antibodies to dengue enhanced for FcgammaRIIIA binding
determine disease severity. Science. 2017;355(6323):395-8.
29. Reicin A, White R, Weinstein SF, Finn AF, Jr., Nguyen H, Peszek I,
et al. Montelukast, a leukotriene receptor antagonist, in combination
with loratadine, a histamine receptor antagonist, in the treatment of
chronic asthma. Archives of internal medicine. 2000;160(16):2481-8.
30. Ciebiada M, Gorska-Ciebiada M, DuBuske LM, Gorski P. Montelukast
with desloratadine or levocetirizine for the treatment of persistent
allergic rhinitis. Annals of allergy, asthma & immunology : official
publication of the American College of Allergy, Asthma, & Immunology.
2006;97(5):664-71.
31. Thangam EB, Jemima EA, Singh H, Baig MS, Khan M, Mathias CB, et al.
The Role of Histamine and Histamine Receptors in Mast Cell-Mediated
Allergy and Inflammation: The Hunt for New Therapeutic Targets.
Frontiers in immunology. 2018;9:1873.
32. Huang H, Li Y, Liang J, Finkelman FD. Molecular Regulation of
Histamine Synthesis. Frontiers in immunology. 2018;9:1392.
33. Merlos M, Giral M, Balsa D, Ferrando R, Queralt M, Puigdemont A, et
al. Rupatadine, a new potent, orally active dual antagonist of histamine
and platelet-activating factor (PAF). The Journal of pharmacology and
experimental therapeutics. 1997;280(1):114-21.